Friday, November 22, 2019

Alembic Pharma gets USFDA nod for generic chronic iron overload treatment tablets

Alembic Pharma gets USFDA nod for generic chronic iron overload treatment tablets The company has received final approvals from the United States Food and Drug Administration (USFDA) for its Deferasirox tablets in the strengths of 90 mg and 360 mg and Deferasirox tablets for oral suspension in the strengths of 125 mg, 250 mg, and 500 mg, Alembic Pharmaceuticals said in a regulatory filing.

from Moneycontrol Business News https://ift.tt/2ObaAo5
Labels:

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)

FII exodus deepens in 2026 at Rs 1.75 lakh crore as April outflows swell to Rs 43,967 crore; FOMC next trigger

Foreign institutional investors offloaded Indian equities worth Rs 17,140 crore last week, extending April's outflows to Rs 43,967 crore...